Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020. The document serves as a transaction notification regarding insider trading activity by a Person Discharging Managerial Responsibilities (PDMR). It does not contain financial results, operational updates, or strategic commentary for the reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of a specific securities transaction and does not include financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single type of event: the acquisition of American Depositary Shares (ADSs) by Dr. H. Barron, Chief Scientific Officer and President, R&D.
Transaction Details and Management Commentary
The filing discloses two related transactions executed on October 29, 2020, on the New York Stock Exchange (XNYS) at a price of $33.96 per ADS:
- Transaction 1: Acquisition of 3,374 ADSs via the GSK 401(k) Plan account.
- Transaction 2: Acquisition of 148,496.714 notional ADSs via the GSK Executive Supplemental Savings Plan account.
Both transactions resulted from Dr. Barron's election to re-allocate funds within his respective retirement accounts to the GSK Stock Fund. There is no management commentary, guidance, or discussion of risks and contingencies in this specific filing.
Investor Verification Checklist
- Verify the total volume of ADSs acquired by Dr. Barron (3,374 actual shares + 148,496.714 notional shares).
- Confirm the transaction date of October 29, 2020, and the execution price of $33.96.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F or earnings releases for financial metrics.